This article is more than 5 years old. Information may no longer be current.

Bioventus secures US distribution rights for GELSYN-3

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bioventus LLC has entered into a multi-year agreement with Institut Biochimique SA, a pharmaceutical company based in Switzerland, to secure the exclusive U.S. distribution rights for GELSYN-3.

According to a company press release, GELSYN-3 is a three-injection, hyaluronic acid (HA) product for pain relief associated with osteoarthritis (OA) of the knee. The pain relief product is indicated for knee pain relief for up to 26 weeks and received premarket approval from the FDA in 2014.

“The addition of GELSYN-3 aligns with our strategy to offer a three-injection HA product to the U.S. market,” Tony Bihl, chief executive officer of Bioventus, said in a press release. “GELSYN-3 gives patients, physicians and payers an effective and safe option for OA pain management. Hyaluronic acid products can help patients live a more active lifestyle and have been shown recently to potentially delay the time to total knee replacement.”

Bioventus plans to enter the three-injection HA market and launch GELSYN-3 in the third quarter of 2016. Financial terms of the transaction were not disclosed.

Reference: www.bioventusglobal.com